MedTrace Logo

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

NCT01239355 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2015-10-05

Study results available
· View outcomes & findings →

Summary

This phase II trial is studying how well MK2206 works in treating patients with advanced liver cancer that did not respond to previous therapy. MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Adult Hepatocellular Carcinoma
  • Advanced Adult Hepatocellular Carcinoma
  • Localized Non-Resectable Adult Liver Carcinoma
  • Recurrent Adult Liver Carcinoma

Interventions

DRUG

Akt Inhibitor MK2206

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Anthony El-Khoueiry, MD · University of Southern California, Norris

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01239355 on ClinicalTrials.gov